Brian Jensen, MD, PI, received a R01, $1.4M direct, grant from the NIH’s National Heart, Lung, and Blood Institute. The researches will investigate how MEK (Mitogen-Activated Protein Kinase Kinase) and drugs that inhibit MEK affect mitochondria within two types of cells: cardiomyocytes (heart muscle cells) and triple-negative breast cancer cells. This study aims to understand the role of MEK and its inhibitors on cellular energy production, survival, and function, particularly focusing on how these interactions may influence heart health and cancer treatment. Co-investigators include William Kim, MD.